+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dyskinesia"

Serotonin 1B receptor agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Serotonin 1B receptor agonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
United States AUSTEDO Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

United States AUSTEDO Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • United States
From
From
Tardive Dyskinesia - Epidemiology Forecast to 2032 - Product Thumbnail Image

Tardive Dyskinesia - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Dyskinesia - Epidemiology Forecast to 2032 - Product Thumbnail Image

Dyskinesia - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
Tardive Dyskinesia Market Report and Forecast 2024-2032 - Product Thumbnail Image

Tardive Dyskinesia Market Report and Forecast 2024-2032

  • Report
  • February 2024
  • 180 Pages
  • Global
From
From
From
Tourette Syndrome Treatment Market - Product Thumbnail Image

Tourette Syndrome Treatment Market

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
From
Tardive Dyskinesia Treatment Market 2024-2028 - Product Thumbnail Image

Tardive Dyskinesia Treatment Market 2024-2028

  • Report
  • November 2023
  • 147 Pages
  • Global
From
From
From
Loading Indicator

Dyskinesia is a neurological disorder characterized by involuntary, repetitive movements. It is most commonly associated with the use of certain central nervous system drugs, such as antipsychotics and levodopa. Dyskinesia can cause a range of physical symptoms, including jerky movements, tremors, and difficulty with coordination. It can also lead to psychological symptoms, such as anxiety and depression. The dyskinesia market is composed of a range of pharmaceutical companies that produce drugs to treat the disorder. These companies develop and market medications that can reduce the severity of symptoms and improve quality of life. Many of these drugs are approved by the FDA and are available in both generic and brand-name forms. Some of the companies in the dyskinesia market include AbbVie, Allergan, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more